Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24461562 | 0.80 | MAPT (0.47) | CNR1MAPTKDM4ETHRBMEN1 | |
| SCHEMBL892836 | 0.80 | OPRM1 (0.53) | OPRM1OPRK1OPRL1CNR1MAPT | |
| SCHEMBL30567991 | 0.80 | OPRM1 (0.53) | OPRM1OPRK1OPRL1CNR1MAPT | |
| Hydrochloric Acid SCHEMBL1703941 | 0.79 | OPRM1 (0.52) | OPRM1OPRK1OPRL1CNR1MAPT | |
| SCHEMBL4334254 | 0.77 | MAPT (0.56) | CNR1MAPTKDM4ETHRBMEN1 | |
| SCHEMBL14401199 | 0.76 | STS (0.53) | CNR1MAPTKDM4ETHRBMEN1 | |
| SCHEMBL19761001 | 0.76 | TLR7 (0.49) | CNR1MAPTKDM4ETHRBSTS | |
| SCHEMBL29555369 | 0.76 | TLR7 (0.49) | CNR1MAPTKDM4ETHRBSTS | |
| SCHEMBL16794930 | 0.75 | CNR1 (0.45) | CNR1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL4771971 | 0.75 | AVPR1A (0.50) | CNR1MAPTKDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315492-B1 | USE OF SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF ALLERGIES | ORTHO MCNEIL PHARM INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7265102-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1309592-B9 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1309592-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050234102-A1 | Substituted pyrazoles | CAI HUI | 2005-10-20 | — | — | US | disclosed |
| US-6951851-B2 | Substituted pyrazoles | CAI HUI | 2005-10-04 | — | — | US | disclosed |
| US-6949540-B2 | Substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-6936603-B2 | Substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040044027-A1 | Substituted pyrazoles | CAI HUI (US) | 2004-03-04 | — | — | US | disclosed |
| US-20030229075-A1 | Substituted pyrazoles | CAI HUI (US) | 2003-12-11 | — | — | US | disclosed |
| US-20030225063-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225062-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6635633-B2 | Substituted pyrazoles | ORTHO-PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6579896-B2 | Immunology response; autoimmune disease | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-17 | — | — | US | disclosed |
| EP-1315492-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309592-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020040019-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020013-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014317-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225062-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | OPRM1 4858/4885OPRK1 4693/4885OPRD1 4703/4885 |
| US-20030229075-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | OPRM1 4858/4885OPRK1 4693/4885OPRD1 4703/4885 |
| US-20020040019-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | OPRM1 4858/4885OPRK1 4693/4885OPRD1 4703/4885 |
| US-20040044027-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | OPRM1 4858/4885OPRK1 4693/4885OPRD1 4703/4885 |
| US-20030225063-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | OPRM1 4858/4885OPRK1 4693/4885OPRD1 4703/4885 |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | OPRM1 4605/4885OPRK1 3202/4885OPRD1 3920/4885 |
| US-20050234102-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | OPRM1 4858/4885OPRK1 4693/4885OPRD1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.